136 related articles for article (PubMed ID: 31705874)
1. Early Quantification of Systemic Inflammatory Proteins Predicts Long-Term Treatment Response to Tofacitinib and Etanercept.
Tomalin LE; Kim J; Correa da Rosa J; Lee J; Fitz LJ; Berstein G; Valdez H; Wolk R; Krueger JG; Suárez-Fariñas M
J Invest Dermatol; 2020 May; 140(5):1026-1034. PubMed ID: 31705874
[TBL] [Abstract][Full Text] [Related]
2. Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis.
Fitz L; Zhang W; Soderstrom C; Fraser S; Lee J; Quazi A; Wolk R; Mebus CA; Valdez H; Berstein G
Clin Exp Dermatol; 2018 Oct; 43(7):790-797. PubMed ID: 29748971
[TBL] [Abstract][Full Text] [Related]
3. Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment.
Kim J; Tomalin L; Lee J; Fitz LJ; Berstein G; Correa-da Rosa J; Garcet S; Lowes MA; Valdez H; Wolk R; Suarez-Farinas M; Krueger JG
J Invest Dermatol; 2018 Feb; 138(2):273-281. PubMed ID: 28927890
[TBL] [Abstract][Full Text] [Related]
4. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
[TBL] [Abstract][Full Text] [Related]
5. Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study.
Valenzuela F; Paul C; Mallbris L; Tan H; Papacharalambous J; Valdez H; Mamolo C
J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):1753-1759. PubMed ID: 27271195
[TBL] [Abstract][Full Text] [Related]
6. Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study.
Krueger J; Clark JD; Suárez-Fariñas M; Fuentes-Duculan J; Cueto I; Wang CQ; Tan H; Wolk R; Rottinghaus ST; Whitley MZ; Valdez H; von Schack D; O'Neil SP; Reddy PS; Tatulych S;
J Allergy Clin Immunol; 2016 Apr; 137(4):1079-1090. PubMed ID: 27059729
[TBL] [Abstract][Full Text] [Related]
7. Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis.
Tan H; Valdez H; Griffins CE; Mrowietz U; Tallman A; Wolk R; Gordon K
J Dermatolog Treat; 2017 Feb; 28(1):3-7. PubMed ID: 27538247
[TBL] [Abstract][Full Text] [Related]
8. IL-1β, IL-17A and combined phototherapy predicts higher while previous systemic biologic treatment predicts lower treatment response to etanercept in psoriasis patients.
Liu Y; Qin G; Meng Z; Du T; Wang X; Tang Y; Cao J
Inflammopharmacology; 2019 Feb; 27(1):57-66. PubMed ID: 30242748
[TBL] [Abstract][Full Text] [Related]
9. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis.
Mamolo C; Harness J; Tan H; Menter A
J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):192-203. PubMed ID: 23294276
[TBL] [Abstract][Full Text] [Related]
10. Association of the Psoriatic Microenvironment With Treatment Response.
Wang G; Miao Y; Kim N; Sweren E; Kang S; Hu Z; Garza LA
JAMA Dermatol; 2020 Oct; 156(10):1057-1065. PubMed ID: 32876657
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions.
Menter A; Papp KA; Tan H; Tyring S; Wolk R; Buonanno M
J Drugs Dermatol; 2014 Mar; 13(3):252-6. PubMed ID: 24595567
[TBL] [Abstract][Full Text] [Related]
12. Validation of the Itch Severity Item as a Measurement Tool for Pruritus in Patients with Psoriasis: Results from a Phase 3 Tofacitinib Program.
Ständer S; Luger T; Cappelleri JC; Bushmakin AG; Mamolo C; Zielinski MA; Tallman AM; Yosipovitch G
Acta Derm Venereol; 2018 Mar; 98(3):340-345. PubMed ID: 29182790
[TBL] [Abstract][Full Text] [Related]
13. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.
Papp KA; Bissonnette R; Gooderham M; Feldman SR; Iversen L; Soung J; Draelos Z; Mamolo C; Purohit V; Wang C; Ports WC
BMC Dermatol; 2016 Oct; 16(1):15. PubMed ID: 27716172
[TBL] [Abstract][Full Text] [Related]
14. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.
Papp KA; Krueger JG; Feldman SR; Langley RG; Thaci D; Torii H; Tyring S; Wolk R; Gardner A; Mebus C; Tan H; Luo Y; Gupta P; Mallbris L; Tatulych S
J Am Acad Dermatol; 2016 May; 74(5):841-50. PubMed ID: 26899199
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis.
Merola JF; Elewski B; Tatulych S; Lan S; Tallman A; Kaur M
J Am Acad Dermatol; 2017 Jul; 77(1):79-87.e1. PubMed ID: 28396102
[TBL] [Abstract][Full Text] [Related]
16. Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis.
Morelli M; Scarponi C; Mercurio L; Facchiano F; Pallotta S; Madonna S; Girolomoni G; Albanesi C
J Immunol Res; 2018; 2018():7897263. PubMed ID: 30581877
[TBL] [Abstract][Full Text] [Related]
17. Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight.
Hutmacher MM; Papp K; Krishnaswami S; Ito K; Tan H; Wolk R; Valdez H; Mebus C; Rottinghaus ST; Gupta P
CPT Pharmacometrics Syst Pharmacol; 2017 May; 6(5):322-330. PubMed ID: 28317328
[TBL] [Abstract][Full Text] [Related]
18. Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis.
Valenzuela F; Papp KA; Pariser D; Tyring SK; Wolk R; Buonanno M; Wang J; Tan H; Valdez H
BMC Dermatol; 2015 May; 15():8. PubMed ID: 25951857
[TBL] [Abstract][Full Text] [Related]
19. Tofacitinib for the treatment of moderate-to-severe psoriasis.
Chiricozzi A; Faleri S; Saraceno R; Bianchi L; Buonomo O; Chimenti S; Chimenti MS
Expert Rev Clin Immunol; 2015 Apr; 11(4):443-55. PubMed ID: 25666451
[TBL] [Abstract][Full Text] [Related]
20. The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib.
Bushmakin AG; Mamolo C; Cappelleri JC; Stewart M
J Dermatolog Treat; 2015 Feb; 26(1):19-22. PubMed ID: 24289224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]